Apogee Therapeutics Inc SEC Filings

Paymentus Holdings, Inc. (PAY) has filed a Form 4 disclosing that its Chairman, President & CEO, Dushyant Sharma, received 1,100,000 Class A RSUs on 07/02/2025 under the company’s 2021 Equity Incentive Plan. Each RSU converts into one share of Class A common stock as it vests. Vesting schedule: one-sixteenth of the award will vest on each quarterly vesting date beginning 15 Aug 2025 (Feb 15, May 15, Aug 15, Nov 15 thereafter), subject to continued service. Following the grant, the reporting person shows 1,100,000 shares owned directly and an additional 1 share held indirectly through Ashigrace LLC, where Sharma holds sole voting and dispositive power. No price was paid for the RSUs, indicating a standard equity-based compensation grant designed to align executive incentives with shareholder value over time.

Apogee Therapeutics (APGE) reported insider stock option grants to directors affiliated with Fairmount Funds Management. On June 17, 2025, two directors received identical stock option packages:

• Peter Harwin and Tomas Kiselak each received options to purchase 14,461 shares at an exercise price of $41.66 per share
• Options will vest on the one-year anniversary of the grant date (June 17, 2026)
• Options expire on June 17, 2035

Both directors hold these options on behalf of Fairmount Funds Management investment vehicles and must turn over any proceeds to Fairmount. Both directors disclaim beneficial ownership except for their pecuniary interest. Fairmount is deemed a director by deputization due to Harwin and Kiselak serving as both board members and Managing Members of Fairmount.

Apogee Therapeutics, Inc. (APGE) – Form 4 insider filing

On 17 June 2025, director Nimish P. Shah received a new stock-option grant covering 14,461 common shares. The option has an exercise price of $41.66, a 10-year term expiring 17 June 2035, and vests in full on the first anniversary of the grant date, contingent on continued service.

The filing lists the transaction as code “A” (acquired), indicating it is an original award rather than a market purchase. No non-derivative share transactions were reported, so Mr. Shah’s direct common-stock position is unchanged.

According to a pre-existing agreement, the option is deemed to be held for the sole benefit of VR Management, LLC. Consequently, both the reporting person and VR Management may be considered indirect beneficial owners. Mr. Shah disclaims beneficial ownership beyond any pecuniary interest.

• No cash consideration was paid for the option (price of derivative security reported as $0.00).
• Ownership is reported as Direct (D), subject to the indirect-beneficial-ownership disclaimer above.

The grant represents normal director compensation and does not, by itself, alter Apogee’s capital structure or have an immediate cash impact. Investor takeaway: routine alignment of director incentives with shareholder value; no material operational or financial effect.

Apogee Therapeutics director Mark C. McKenna received a stock option grant on June 17, 2025, according to a Form 4 filing. The derivative securities transaction details include:

• Granted 14,461 stock options to purchase common stock
• Exercise price set at $41.66 per share
• Options will vest fully on the one-year anniversary of the grant date (June 17, 2026)
• Options expire on June 17, 2035
• Vesting is contingent on continued service with the company

The transaction represents a standard director compensation equity grant. The filing was signed by Matthew Batters as attorney-in-fact for McKenna on June 20, 2025. McKenna holds these options under direct ownership.

Apogee Therapeutics (APGE) filed a Form 4 disclosing that director William A. Jones Jr. received a grant of 14,461 non-qualified stock options on 17 June 2025. The options carry an exercise price of $41.66 and expire on 17 June 2035. According to the filing, the award vests 100 % on the first anniversary of the grant date, contingent upon Mr. Jones’ continued service. The transaction increases his derivative holdings to 14,461 options; there was no concurrent acquisition or disposition of common shares. Because this is a routine director equity grant with no immediate cash outlay, it does not directly affect Apogee’s share count, earnings or cash flow, but it modestly aligns the director’s incentives with future shareholder value.

Andrew Gottesdiener, Director at Apogee Therapeutics, received a stock option grant to purchase 14,461 shares of common stock at an exercise price of $41.66 per share on June 17, 2025.

Key details of the option grant:

• Exercise price: $41.66 per share
• Vesting: 100% on one-year anniversary of grant date
• Expiration date: June 17, 2035
• Subject to continued service with the company

Notable arrangement: The options are held under an agreement with VR Management, LLC, where Gottesdiener must exercise the options solely at their direction. VR Management is entitled to the underlying shares, with Gottesdiener disclaiming beneficial ownership except for his pecuniary interest.

Apogee Therapeutics director Jennifer A. Fox received a stock option grant on June 17, 2025. The derivative security details include:

• Right to purchase 14,461 shares of common stock
• Exercise price set at $41.66 per share
• Options will vest in full on the one-year anniversary of the grant date (June 17, 2026)
• Expiration date is June 17, 2035
• Total grant value at $0.00 cost to the director

The vesting is contingent upon Fox's continued service with Apogee Therapeutics. The Form 4 was filed through an attorney-in-fact, Matthew Batters, on June 20, 2025. This equity compensation grant aligns with standard director compensation practices and creates long-term alignment with shareholder interests.

Form 4 Filing Details: Lisa Bollinger, Director at Apogee Therapeutics (NASDAQ: APGE), received a stock option grant on June 17, 2025. The derivative securities transaction involves the right to purchase 14,461 shares of common stock at an exercise price of $41.66 per share.

The stock option grant has the following key terms:

• Exercise price: $41.66 per share
• Expiration date: June 17, 2035
• Vesting schedule: 100% vesting on the one-year anniversary of the grant date
• Vesting condition: Subject to continued service with the company

The filing was signed by Matthew Batters as attorney-in-fact for Lisa Bollinger on June 20, 2025. This represents a standard equity compensation grant for a board member, structured as a ten-year option with cliff vesting.

On 17 June 2025 Apogee Therapeutics, Inc. (Nasdaq: APGE) held its 2025 Annual Meeting of Stockholders. Shareholders elected three Class II directors—Dr Lisa Bollinger (35.1 M votes for), Tomas Kiselak (39.2 M) and Nimish Shah (25.8 M)—to serve until the 2028 meeting; abstentions ranged from 0.2 M to 13.6 M and 1.8 M broker non-votes were recorded for each nominee.

Ernst & Young LLP was ratified as independent auditor for fiscal 2025 with 41.16 M votes in favor (99.9%), 3,099 against and 26,229 abstentions.

In the non-binding vote on the frequency of future “say-on-pay” proposals, a decisive 39.35 M shares (≈99%) supported annual advisory votes; the Board will adopt this cadence going forward.

No financial results, strategic transactions or other material events were disclosed. The filing is routine corporate-governance housekeeping and is unlikely to affect the company’s valuation or near-term outlook.